{"filings":[{"id":94522,"accession_number":"0001477932-26-002252","cik":1663038,"company_name":"Quantum Genesis AI Corp.","ticker":"QTZM","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Quantum Genesis AI confirms CEO assignment of ibuprofen synthesis patent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Naveen Kulkarni assigned all rights in US Patent App. US20250146029A1 for enzymatic ibuprofen synthesis to the company.","Assignment effective as of Nov. 2, 2023, formalizing a prior 2023 Asset Purchase Agreement.","Company will amend FY2025 10-K and FY2026 Q1 & Q2 10-Qs to update IP disclosures.","No new consideration; agreement confirms existing ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5740000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106965,"accession_number":"0001477932-26-000821","cik":1663038,"company_name":"Quantum Genesis AI Corp.","ticker":"QTZM","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Quantumzyme Corp. changes name to Quantum Genesis AI Corp., ticker to QGAI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change approved by holder of 79.56% voting power via written consent on Nov 30, 2025.","OTC trading symbol changes to QGAI effective Feb 17, 2026, as announced by FINRA on Feb 13, 2026.","Certificate of Amendment filed with Nevada Secretary of State on Feb 11, 2026; effective upon filing.","No change to authorized capital, shares outstanding, par value, or CUSIP number."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5740000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106964,"accession_number":"0001477932-26-000072","cik":1663038,"company_name":"Quantum Genesis AI Corp.","ticker":"QTZM","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.03"],"status":"ready","headline":"Quantumzyme Corp. changing name to Quantum Genesis AI Corp., pending regulatory approvals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved name change to Quantum Genesis AI Corp. on Nov 30, 2025; majority shareholder consented.","Certificate of Amendment not yet filed; effective after SEC 14C process and 20-day waiting period.","FINRA notification filed; new ticker symbol to be assigned upon completion of review.","Name change does not affect shareholder rights, authorized shares, par value, or CUSIP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5740000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}